A Phase 3 interventional study of GONAL-f® in Infertility, Ovulation Induction and In-Vitro Fertilization, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2018-04-06.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 11th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 11th registered.
2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
Nanjing University · Sites in China
Ages 35–40 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 43 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2004, is one of 11 in phase 3, and was the 30th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
This was a prospective, open-label, non-comparative, Phase IIIb trial to assess the convenience, safety and efficacy of the new Gonal-F fbm [recombinant follicle stimulating hormone (r-FSH)] liquid formulation, in common setting for ovulation induction (OI) and also in in-vitro fertilization (IVF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GONAL-f®
GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
Also known as: Follitropin alpha
Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)
Number of subjects who self-administered the IMP were presented in this outcome measure.
Time frame: Up to 1 year
Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator
Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction.
Time frame: Up to 1 year
Evaluation of the Information Given to the Subjects on the Pen's Utilization
Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory.
Time frame: Up to 1 year
Duration of Ovarian Stimulation With GONAL-f®
Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment.
Time frame: Up to 1 year
Mean Number of Embryos Transferred
Time frame: End of Stimulation period (up to a maximum 26 days)
Total and Average Daily Dose of GONAL-f®
Time frame: Up to 26 days
Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI)
Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation.
Time frame: Up to 20 Weeks of Gestation
Number of Subjects With Live Birth
Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported.
Time frame: End of Gestation period, assessed up to a maximum of 1 year
Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator
Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma.
Time frame: Up to 1 year
Number of Subjects With at Least 1 Adverse Event
An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered.
Time frame: Up to 1 year
Number of Subjects Taking at Least 1 Concomitant Treatment
Time frame: Up to 1 year
| Milestone | GONAL-f® |
|---|---|
| Started | 215 |
| Intention to treat (itt) population | 204 |
| Completed | 65 |
| Not completed | 150 |
| Withdrew: Protocol violation | 115 |
| Withdrew: Withdrawal by subject | 19 |
| Withdrew: Subject questionnaires not returned | 5 |
| Withdrew: Subjects enrolled, but not treated | 11 |
Number of subjects who self-administered the IMP were presented in this outcome measure.
| subjects | GONAL-f® |
|---|---|
| Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP) | 159 |
Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction.
| subjects | GONAL-f® |
|---|---|
| Very satisfactory | 101 |
| Satisfactory | 93 |
| Average satisfaction | 1 |
Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory.
| subjects | GONAL-f® |
|---|---|
| Training Session: Very satisfactory | 89 |
| Training Session: Satisfactory | 95 |
| Training Session: Unsatisfactory | 5 |
| Training Session: Very unsatisfactory | 1 |
| Information brochure: Very satisfactory | 95 |
| Information brochure: Satisfactory | 89 |
| Information brochure: Unsatisfactory | 9 |
| Information brochure: Very unsatisfactory | 2 |
Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment.
| days | GONAL-f® |
|---|---|
| Duration of Ovarian Stimulation With GONAL-f® | 10 (3 to 26) |
| embryos | GONAL-f® |
|---|---|
| Mean Number of Embryos Transferred | 1.8 ± 0.7 |
| International Units (IU) | GONAL-f® |
|---|---|
| Total dose | 1527 ± 964 |
| Daily dose | 149.5 ± 75.9 |
Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation.
| Percentage of subjects | GONAL-f® |
|---|---|
| Clinical pregnancy | 16.5 (8.6 to 24.4) |
| Biochemical pregnancy | 16.5 (8.6 to 24.4) |
| Ongoing pregnancy | 16.5 (8.6 to 24.4) |
Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported.
| subjects | GONAL-f® |
|---|---|
| Number of Subjects With Live Birth | 41 |
Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma.
| subjects | GONAL-f® |
|---|---|
| Pain | 32 |
| Swelling/welt | 3 |
| Redness | 34 |
| Itch | 8 |
| Haematoma | 41 |
An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered.
| subjects | GONAL-f® |
|---|---|
| Number of Subjects With at Least 1 Adverse Event | 36 |
| subjects | GONAL-f® |
|---|---|
| Number of Subjects Taking at Least 1 Concomitant Treatment | 28 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GONAL-f® | — | 6/215 (2.8%) | 36/215 (16.7%) |
| Event | GONAL-f® |
|---|---|
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 2/215 |
| Abortion spontaneous NOSPregnancy, puerperium and perinatal conditions | 1/215 |
| Placental, amniotic and cavity disordersPregnancy, puerperium and perinatal conditions | 1/215 |
| Uterine contractions during pregnancyPregnancy, puerperium and perinatal conditions | 1/215 |
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 1/215 |
| Uterine dilation and curettageSurgical and medical procedures | 1/215 |
| Event | GONAL-f® |
|---|---|
| Injection site haemorrhageGeneral disorders | 15/215 |
| Injection site erythemaGeneral disorders | 4/215 |
| Injection site painGeneral disorders | 4/215 |
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 4/215 |
| Abortion spontaneous NOSPregnancy, puerperium and perinatal conditions | 3/215 |
| Injection site pruritusGeneral disorders | 2/215 |
| Abdominal pain upperGastrointestinal disorders | 1/215 |
| NauseaGastrointestinal disorders | 1/215 |
| AstheniaGeneral disorders | 1/215 |
| Pelvic infectionInfections and infestations | 1/215 |
The ITT population included all the subjects who received at least 1 dose of the IMP.
| Age, Continuous(years) | GONAL-f® |
|---|---|
| Mean | 30.0 ± 3.3 |
| Sex: Female, Male(Participants) | GONAL-f® |
|---|---|
| Female | 204 |
| Male | 0 |
Ran from May 2004 to primary completion in Mar 2006, 21 months.
Results were first posted in Apr 2018, 12 years 1 month after primary completion.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Merck KGaA, Darmstadt, Germany →